Biolumpivaxin | Lumpy Skin Disease

Biolumpivaxin

A vaccine for lumpy skin disease, developed in collaboration between Bharat Biotech’s group firm and ICAR, has received a license from CDSCO.

  • World’s 1st DIVA (Differentiating Infected from Vaccinated Animals) marker vaccine for Lumpy Skin Disease.
  • Developed by Biovet, a Bharat Biotech group firm.DIVA Technology: Differentiates between naturally infected and vaccinated animals. Aids in disease surveillance and control programs.
  • Single-Dose Regimen: Administered once a year to cattle and buffaloes above 3 months of age.
  • High Safety and Efficacy: Rigorously tested for quality, safety, and effectiveness.
  • vector-borne pox disease
  • Not a zoonotic disease
  • Aim – To protect cattle against LSD virus.
  • Caused by – virus
  • Infects cattle and water buffalo
  • Vectors – Blood-feeding insects.
  • Endemic in most African countries
  • Had spread in Middle East, Southeast Europe and West and Central Asia.
  • 1st observed – Zambia (1929)
  • 1st time in India – Odisha (2019)
  • Vaccine – Lumpi-ProVacInd vaccine
    • homologouslive attenuated vaccine developed by Indian Council of Agricultural Research (ICAR).
  • DIVA Vaccines: Allow for differentiation between naturally infected and vaccinated animals.
  • Usage: Widely used in livestock disease control programs to prevent outbreaks, enable disease surveillance, and aid eradication efforts.
  • Advantages:
    • Easier to spot infected animals, relax restrictions for vaccinated ones.
    • Track virus spread in vaccinated populations.
  • Disadvantages:
    • Might be less effective than regular vaccines.
    • Requires special, less sensitive tests.
Type of VaccineDefinition
Inactivated VaccinesUse killed germs to cause immune response.
Live-attenuated VaccinesUse weakened germs to cause immune response.
mRNA VaccinesUse messenger RNA to produce proteins triggering immunity.
Subunit, Recombinant, Polysaccharide, and Conjugate VaccinesUse specific pieces of germs for strong immune response.
Toxoid VaccinesUse toxins made by germs to create immunity.
Viral Vector VaccinesUse modified viruses as vectors to deliver protection.

  • Use the killed version of the germ causing a disease.
  • Created by inactivating a pathogen using heat or chemicals (formaldehyde/formalin).
  • Pathogen’s ability to replicate is destroyed, but it remains “intact” for immune recognition.
  • Generally referred to as “inactivated” rather than “killed” for viral vaccines.
  • Immunity may not be as strong as live vaccines; booster shots may be required.
  • Used to protect: Hepatitis A, Flu (shot only), Polio (shot only), Rabies.
  • Use a weakened (attenuated) form of the germ causing a disease.
  • Create a strong and long-lasting immune response similar to natural infection.
  • Not suitable for people with weakened immune systems.
  • Used to protect: Measles, Mumps, Rubella (MMR), Rotavirus, Smallpox.
  • mRNA vaccines produce proteins to trigger an immune response.
  • Benefits: Shorter manufacturing times, no risk of causing disease.
  • Used to protect: Covid-19.
  • Use specific pieces of the germ (protein, sugar, capsid).
  • Provide a strong immune response.
  • Suitable for people with weakened immune systems and long-term health problems.
  • Used to protect: Hib (Haemophilus influenzae type b), Hepatitis B, HPV, Pneumococcal disease.
  • Use a toxin produced by the germ causing a disease.
  • Create immunity to the toxin rather than the germ itself.
  • Used to protect: Diphtheria, Tetanus.
  • Use a modified version of a different virus as a vector for protection.
  • Various viruses used as vectors: influenza, VSV, measles virus, adenovirus.
  • Adenovirus used in some Covid-19 vaccines.
  • Used to protect: Covid-19.

Source: The Hindu


Previous Year Question

In the context of vaccines manufactured to prevent COVID-19 pandemic, consider the following statements:
1. The Serum Institute of India produced COVID-19 vaccine named Covishield using mRNA platform.
2. Sputnik V vaccine is manufactured using vector based platform.
3. COVAXIN is an inactivated pathogen based vaccine.
Which of the statements given above are correct?

[UPSC CSE – 2022 Prelims]

(a) 1 and 2 only
(b) 2 and 3 only
(c) 1 and 3 only
(d) 1, 2 and 3

Answer: (b)
Explanation:
Statement 1 is incorrect:
Covishield vaccine is based on the platform which uses a recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 Spike (S) glycoprotein.


Leave a Reply

Your email address will not be published. Required fields are marked *